Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

FRIDAY, June 6, 2025 (HealthDay News) — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Autolus Therapeutics plc delivers a breakthrough CAR-T therapy for B-ALL with strong safety/efficacy. Learn more about AUTL ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The karaoke scene in the finale of The Handmaid's Tale may have confused some fans, but it actually calls back to a pivotal ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Hulu's The Handmaid's Tale has finally concluded its sixth season after eight years of its premiere. The show, based on ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...